[ad_1]
DUBLIN – (COMMERCIAL THREAD) – The report “Nucleic Acid Therapy CDMO Market – A Global and Regional Analysis: Product, Technology and End User Focus – Analysis and Forecast, 2021-2030” has been added to ResearchAndMarkets.com offer.
The global nucleic acid-based therapeutic CDMO market was valued at $ 1,546.4 million in FY2020 and is expected to reach $ 4,463.7 million by 2030.
The completion of the sequencing of the human genome and the elucidation of molecular pathways that are critical in the molecule-disease interaction have offered unprecedented opportunity and growth for the development of nucleic acid-based therapies. However, to keep up with the manufacture and development of such therapies, pharmaceutical companies have established partnerships with the Contract Manufacturing and Development Company (CDMO) which are viable alternatives to internal drug development. In addition, the success of the respective business model has also led these CDMOs to become an integral part of the value chain of these pharmaceutical companies.
The growing desire to outsource drug development to CDMOs and the growing need for pharmaceuticals has driven the expansion of the global nucleic acid based therapeutic CDMO market.
Over the past decade, there has been a tremendous increase in the amount of genetic sequence information that has the potential to revolutionize the way diseases are categorized and treated. Traditional diagnoses, largely anatomical or descriptive in nature, are likely to be replaced by molecular characterization of the disease. The fact that certain genes drive key disease processes will also allow for the rational design of gene-specific therapies. Antisense oligonucleotides represent a technology that can play several roles in this process. In addition, at present, there are 16 Nucleic Acid Therapies approved by the FDA and EMA and many more are in development, which involves the trust and acceptance of the use of such therapies on the market.
Market growth drivers
-
Acceleration of the transition of the pharmaceutical market towards innovative biological and cellular products and gene therapy
-
Reduction of the overall manufacturing cost in CDMOs
-
Growing Endorsements of Nucleic Acid Therapies
Market challenges
-
Lack of expertise in the manufacture of nucleic acid
-
Supply chain and logistics challenges
-
Difficult therapeutic classification due to the wide variety of nucleic acids
Market opportunities
-
Growing Trend in Outsourcing Among Pharmaceutical Companies
-
Accelerate research and development with technology
-
Growth in developing countries
Key questions addressed in this report:
-
What are the different types of nucleic acid therapies available in the global CDMO nucleic acid therapy market?
-
What are the main development strategies implemented by the main players to stand out in this global nucleic acid therapeutic CDMO market?
-
What are the manufacturing sites of the key companies in the global Nucleic Acid Therapeutic CDMO market?
-
What are the different manufacturing technologies in the global Nucleic Acid Therapeutic CDMO market?
-
How have strategic collaborations between key players spurred product development in the global nucleic acid-based therapeutic CDMO market?
-
Who are the major companies dominating the global nucleic acid based therapeutic CDMO market?
-
Based on the type of product, which therapy in the global Nucleic Acid Therapeutic CDMO market is expected to experience massive increase in demand during the forecast period?
-
How is each segment of the global Nucleic Acid Therapeutic CDMO market expected to grow during the forecast period, and what revenue is expected to be generated by each of these segments by the end of 2030?
Main topics covered:
1 Markets
1.1 Industry outlook
1.2 Definition of the product
1.3 Global Nucleic Acid Therapy CDMO Market Footprint, (USD Million), 2020-2030
1.4 Current landscape of nucleic acid therapeutic CDMOs
1.5 Significant use of nucleic acid in therapy
1.6 Types of nucleic acids synthesized for therapeutic purposes
1.7 Market dynamics
1.7.1 Market Drivers
1.7.1.1 Acceleration of the transition of the pharmaceutical market towards innovative biological and cellular products and gene therapy
1.7.1.2 Reduction of the overall manufacturing cost in CDMOs
1.7.1.3 Growing Endorsements of Nucleic Acid Therapies
1.7.2 Constraints
1.7.2.1 Lack of expertise in the manufacture of nucleic acids
1.7.2.2 Supply chain and logistics challenges
1.7.2.3 Therapeutic classification difficult due to the wide variety of nucleic acids
1.7.3 Opportunities
1.7.3.1 Growing Trend of Outsourcing Among Pharmaceutical Companies
1.7.3.2 Accelerate research and development alongside technology
1.7.3.3 Growth in developing countries
2 Competitive landscape
3 Method of chemical synthesis
4 Technology
5 End user
6 products
7 regions
8 markets – Competitive benchmarking and company profiles
-
Agilent Technologies, Inc.
-
Ajinomoto Co. Inc.
-
Bachem Holding SA
-
Biospring GmbH
-
Corden Pharma International
-
Danaher Company
-
Guangzhou Ruibo Biotechnology Co., Ltd.
-
KNC Laboratories Co., Ltd.
-
LGC Limited
-
Merck KGaA
-
Nippon Shokubai Co., Ltd.
-
Nitto Denko Avecia Inc.
-
QIAGEN SA
-
ST Pharm Co Ltd
-
Sumitomo Chemical Co., Ltd.
-
Syngene International Limited
-
Thermo Fisher Scientific Inc.
-
Wuxi AppTec
-
Yamasa Company
For more information on this report, visit https://www.researchandmarkets.com/r/1×5210
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for market research reports and international market data. We provide you with the latest data on international and regional markets, key industries, major companies, new products and the latest trends.
[ad_2]
